276 related articles for article (PubMed ID: 19101783)
1. Efficacy and safety of optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in patients with non-ST segment elevation acute coronary syndromes in clinical practice.
Heer T; Juenger C; Gitt AK; Bauer T; Towae F; Zahn R; Senges J; Zeymer U;
J Thromb Thrombolysis; 2009 Oct; 28(3):325-32. PubMed ID: 19101783
[TBL] [Abstract][Full Text] [Related]
2. Unfractionated heparin-clopidogrel combination in ST-elevation myocardial infarction not receiving reperfusion therapy.
Bugiardini R; Dorobantu M; Vasiljevic Z; Kedev S; Knežević B; Miličić D; Calmac L; Trninic D; Daullxhiu I; Cenko E; Ricci B; Puddu PE; Manfrini O; Koller A; Badimon L;
Atherosclerosis; 2015 Jul; 241(1):151-6. PubMed ID: 25988359
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Harrington RA; Becker RC; Cannon CP; Gutterman D; Lincoff AM; Popma JJ; Steg G; Guyatt GH; Goodman SG
Chest; 2008 Jun; 133(6 Suppl):670S-707S. PubMed ID: 18574276
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.
Sabatine MS; Morrow DA; Dalby A; Pfisterer M; Duris T; Lopez-Sendon J; Murphy SA; Gao R; Antman EM; Braunwald E;
J Am Coll Cardiol; 2007 Jun; 49(23):2256-63. PubMed ID: 17560290
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: a systematic review and meta-analysis.
Galli M; Andreotti F; D'Amario D; Vergallo R; Vescovo GM; Giraldi L; Migliaro S; Ameri P; Porto I; Crea F
Eur Heart J Cardiovasc Pharmacother; 2020 Jan; 6(1):43-56. PubMed ID: 31350546
[TBL] [Abstract][Full Text] [Related]
6. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis.
Rogowski W; Burch J; Palmer S; Craigs C; Golder S; Woolacott N
Health Technol Assess; 2009 Jun; 13(31):iii-iv, ix-xi, 1-77. PubMed ID: 19573471
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC
Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655
[TBL] [Abstract][Full Text] [Related]
8. Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction.
Ng FH; Tunggal P; Chu WM; Lam KF; Li A; Chan K; Lau YK; Kng C; Keung KK; Kwan A; Wong BC
Am J Gastroenterol; 2012 Mar; 107(3):389-96. PubMed ID: 22108447
[TBL] [Abstract][Full Text] [Related]
9. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Harrington RA; Becker RC; Ezekowitz M; Meade TW; O'Connor CM; Vorchheimer DA; Guyatt GH
Chest; 2004 Sep; 126(3 Suppl):513S-548S. PubMed ID: 15383483
[TBL] [Abstract][Full Text] [Related]
10. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin.
Cohen M; Théroux P; Borzak S; Frey MJ; White HD; Van Mieghem W; Senatore F; Lis J; Mukherjee R; Harris K; Bigonzi F;
Am Heart J; 2002 Sep; 144(3):470-7. PubMed ID: 12228784
[TBL] [Abstract][Full Text] [Related]
11. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.
Danchin N; Aïssaoui N
Cardiovasc Drugs Ther; 2010 Aug; 24(4):325-30. PubMed ID: 20714797
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.
Cannon CP; Husted S; Harrington RA; Scirica BM; Emanuelsson H; Peters G; Storey RF;
J Am Coll Cardiol; 2007 Nov; 50(19):1844-51. PubMed ID: 17980250
[TBL] [Abstract][Full Text] [Related]
14. Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.
Mehta SR; Bassand JP; Chrolavicius S; Diaz R; Fox KA; Granger CB; Jolly S; Rupprecht HJ; Widimsky P; Yusuf S;
Am Heart J; 2008 Dec; 156(6):1080-1088.e1. PubMed ID: 19033002
[TBL] [Abstract][Full Text] [Related]
15. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
Silva MA; Donovan JL; Gandhi PJ; Volturo GA
Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
Blazing MA; de Lemos JA; White HD; Fox KA; Verheugt FW; Ardissino D; DiBattiste PM; Palmisano J; Bilheimer DW; Snapinn SM; Ramsey KE; Gardner LH; Hasselblad V; Pfeffer MA; Lewis EF; Braunwald E; Califf RM;
JAMA; 2004 Jul; 292(1):55-64. PubMed ID: 15238591
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention.
Denardo SJ; Davis KE; Tcheng JE
Am J Cardiol; 2007 Nov; 100(9):1376-82. PubMed ID: 17950793
[TBL] [Abstract][Full Text] [Related]
18. Optimizing antithrombotic therapy in patients with non-ST-segment elevation acute coronary syndrome.
Dobesh PP; Phillips KW; Haines ST
Am J Health Syst Pharm; 2008 Aug; 65(15 Suppl 7):S22-8. PubMed ID: 18653821
[TBL] [Abstract][Full Text] [Related]
19. Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial.
Zeymer U; Gitt A; Jünger C; Bauer T; Heer T; Koeth O; Mark B; Zahn R; Senges J; Gottwik M
Thromb Haemost; 2008 Jan; 99(1):155-60. PubMed ID: 18217148
[TBL] [Abstract][Full Text] [Related]
20. Arterial antithrombotic effects of aspirin, heparin, enoxaparin and clopidogrel alone, or in combination, in the rat.
Daykin HJ; Sturgeon SA; Jones C; Wright CE
Thromb Res; 2006; 118(6):755-62. PubMed ID: 16410020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
